• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

    6/20/24 5:29:09 AM ET
    $ARQT
    $DJT
    $HDL
    $OCGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Programming Data Processing
    Technology
    Get the next $ARQT alert in real time by email

    U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.

    Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell sharply in today's pre-market trading after the company rejected unsolicited takeover bids, citing undervaluation.

    Vanda Pharmaceuticals shares dipped 6% to $5.96 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Trump Media & Technology Group Corp. (NASDAQ:DJT) shares dipped 7.7% to $28.89 in pre-market trading. Trump Media & Technology Group shares dipped around 10% on Tuesday after the U.S. SEC declared effectiveness of the registration statement on Form S-1 related to the resale by certain securityholders of certain shares and warrants.
    • Super Hi International Holding (NASDAQ:HDL) shares fell 4.6% to $16.49 in pre-market trading. On Tuesday, Super Hi International posted a first-quarter loss of 1 cent per share on sales of $187.60 million.
    • Ocugen, Inc. (NASDAQ:OCGN) fell 4.4% to $1.32 in pre-market trading after gaining 3% on Tuesday.
    • Qiagen N.V. (NYSE:QGEN) fell 4.3% to $41.87 in pre-market trading after reporting quarterly results. On Monday, Qiagen announced at its Capital Markets Day a comprehensive strategy aimed at delivering solid and profitable growth through 2028. The company targets a 7% compound annual sales growth at constant exchange rates (CER) by 2028.
    • STMicroelectronics N.V. (NYSE:STM) declined 4.2% to $41.29 in pre-market trading. On Tuesday, Goldman Sachs analyst Alexander Duval upgraded STMicroelectronics from Sell to Neutral and raised the price target from $35.5 to $45.8.
    • SolarEdge Technologies, Inc. (NASDAQ:SEDG) shares slipped 3.2% to $35.87 in pre-market trading. SolarEdge Technologies announced the German launch of its high-power SolarEdge TerraMax™ Inverter combined with H1300 Power Optimizers.
    • Arcutis Biotherapeutics Inc (NASDAQ:ARQT) shares fell 3.1% to $7.90 in pre-market trading.

    Now Read This: Hewlett Packard Enterprise, Accenture And 3 Stocks To Watch Heading Into Thursday

    Don't forget to check out our premarket coverage here

    Get the next $ARQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQT
    $DJT
    $HDL
    $OCGN

    CompanyDatePrice TargetRatingAnalyst
    SolarEdge Technologies Inc.
    $SEDG
    2/19/2026$38.00 → $43.00Buy
    TD Cowen
    Qiagen N.V.
    $QGEN
    1/22/2026$54.00Buy → Hold
    Deutsche Bank
    SolarEdge Technologies Inc.
    $SEDG
    1/13/2026Mkt Perform
    Raymond James
    SolarEdge Technologies Inc.
    $SEDG
    1/9/2026$38.00Hold → Buy
    TD Cowen
    SolarEdge Technologies Inc.
    $SEDG
    12/16/2025$33.00Underweight → Equal-Weight
    Morgan Stanley
    Qiagen N.V.
    $QGEN
    12/11/2025$50.00Buy → Neutral
    Citigroup
    STMicroelectronics N.V.
    $STM
    11/25/2025$22.00Neutral
    Mizuho
    SolarEdge Technologies Inc.
    $SEDG
    11/6/2025$26.00 → $34.00Hold
    TD Cowen
    More analyst ratings

    $ARQT
    $DJT
    $HDL
    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and Secretary Glabe Scott bought $10,465 worth of shares (1,000 units at $10.46), increasing direct ownership by 0.31% to 326,236 units (SEC Form 4)

    4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)

    11/19/25 8:48:25 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $DJT
    $HDL
    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

    Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WESTLAKE VILLAGE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innov

    2/24/26 9:15:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

    WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity (NCE) that belongs in the class of atypical antipsychotics. In clinical studies BYSANTI™ demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum enabling it to leverage well

    2/20/26 5:59:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yorkville America Equities, LLC and Truth Social Funds Announce Proposed Acquisition of the Point Bridge America First ETF (MAGA)

    SARASOTA, Fla., Feb. 19, 2026 /PRNewswire/ -- Yorkville America Equities, LLC ("Yorkville"), investment adviser for the Truth Social Funds, today announced that it has entered into an agreement to acquire the Point Bridge America First ETF (Ticker: MAGA) into the Truth Social Funds product suite. The respective Board of Trustees of the Truth Social Funds and ETF Series Solutions have approved this transaction, which, if approved by shareholders, is expected to close in Q2 2026. The Truth Social Funds and each of its existing ETF series are part of the Truth.Fi fintech brand from Trump Media & Technology Group Corp. (Nasdaq, NYSE Texas: DJT) ("Trump Media"), operator of the social media platf

    2/19/26 9:00:00 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    $ARQT
    $DJT
    $HDL
    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Honore Tage sold $240,900 worth of shares (30,000 units at $8.03), decreasing direct ownership by 24% to 93,469 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    2/24/26 4:28:24 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Marketing Officer Wijkstrom Joakim was granted 125,000 shares, increasing direct ownership by 52% to 364,269 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    2/19/26 5:53:58 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Business Development Birznieks Gunther was granted 125,000 shares, increasing direct ownership by 30% to 536,628 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    2/19/26 5:51:59 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $DJT
    $HDL
    $OCGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $DJT
    $HDL
    $OCGN
    SEC Filings

    View All

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    2/23/26 7:00:24 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    2/19/26 4:31:34 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SolarEdge Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SOLAREDGE TECHNOLOGIES, INC. (0001419612) (Filer)

    2/18/26 7:38:06 AM ET
    $SEDG
    Semiconductors
    Technology

    $ARQT
    $DJT
    $HDL
    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on SolarEdge Technologies with a new price target

    TD Cowen reiterated coverage of SolarEdge Technologies with a rating of Buy and set a new price target of $43.00 from $38.00 previously

    2/19/26 6:53:08 AM ET
    $SEDG
    Semiconductors
    Technology

    Qiagen downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Qiagen from Buy to Hold and set a new price target of $54.00

    1/22/26 8:26:25 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on SolarEdge Technologies

    Raymond James initiated coverage of SolarEdge Technologies with a rating of Mkt Perform

    1/13/26 9:17:42 AM ET
    $SEDG
    Semiconductors
    Technology

    $ARQT
    $DJT
    $HDL
    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN Appoints Mark Stevenson to Supervisory Board

    QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma

    1/26/26 4:05:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Resolutions approved at the Extraordinary General Meeting of Shareholders

    Resolutions approved at the Extraordinary General Meeting of Shareholders Amsterdam, December 18, 2025 - STMicroelectronics (NYSE:STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced the results related to the voting items of the Extraordinary General Meeting of Shareholders (EGM) which was held today in Amsterdam. The proposed resolutions were both approved by the Shareholders: the appointment of Armando Varricchio, as member of the Supervisory Board, for a term expiring at the end of the 2028 AGM; and the appointment of Orio Bellezza, as member of the Supervisory Board, for a term expiring at the end of the 2028 AGM. The age

    12/18/25 11:30:00 AM ET
    $STM
    Semiconductors
    Technology

    $ARQT
    $DJT
    $HDL
    $OCGN
    Financials

    Live finance-specific insights

    View All

    SolarEdge Announces Fourth Quarter and Full Year 2025 Financial Results

    SolarEdge Technologies, Inc. (NASDAQ:SEDG), a global leader in smart energy technology, today announced its financial results for the fourth quarter and year ended December 31, 2025. "Our fourth quarter results delivered 70% year-over-year revenue growth, marking our fourth consecutive quarter of year-over-year revenue growth and fifth consecutive quarter of margin expansion," said Shuki Nir, CEO of SolarEdge. "In 2025 we restored discipline, generated strong free cash flow, and rebuilt margins. In 2026 we are shifting decisively to offense, focused on moving toward profitable growth and capturing global market share through the rollout of the SolarEdge Nexis platform. By leveraging our D

    2/18/26 7:30:00 AM ET
    $SEDG
    Semiconductors
    Technology

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $DJT
    $HDL
    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trump Media & Technology Group Corp.

    SC 13G/A - Trump Media & Technology Group Corp. (0001849635) (Subject)

    11/14/24 9:53:48 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SolarEdge Technologies Inc.

    SC 13G/A - SOLAREDGE TECHNOLOGIES, INC. (0001419612) (Subject)

    11/14/24 4:38:03 PM ET
    $SEDG
    Semiconductors
    Technology